Src inhibitor dasatinib synergizes with trametinib to induce cell cycle arrest and apoptosis by downregulating TAZ in KRAS-mutant cancer cells, but not in wild type KRAS or EGFR mutant cancer cells 165. This evidence concerns the gene KRAS and cancer.